Headlands Technologies LLC purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 6,280 shares of the medical research company's stock, valued at approximately $3,149,000.
Several other large investors also recently made changes to their positions in TMO. J. Stern & Co. LLP raised its stake in shares of Thermo Fisher Scientific by 58,006.4% in the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock valued at $18,258,082,000 after acquiring an additional 31,455,105 shares in the last quarter. BlackRock Inc. acquired a new position in Thermo Fisher Scientific during the second quarter valued at approximately $15,501,867,000. Corient Private Wealth LP bought a new position in shares of Thermo Fisher Scientific in the second quarter valued at approximately $382,547,000. Norges Bank acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $3,072,744,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth $1,974,561,000. Institutional investors own 89.23% of the company's stock.
Wall Street Analysts Forecast Growth
Several brokerages recently commented on TMO. Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating on the stock in a report on Friday, May 8th. KeyCorp reaffirmed an "overweight" rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Morgan Stanley lifted their price objective on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an "overweight" rating in a research note on Friday, July 24th. Barclays increased their target price on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an "overweight" rating in a research note on Friday, July 24th. Finally, Wolfe Research initiated coverage on Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $619.41.
Read Our Latest Research Report on Thermo Fisher Scientific
Thermo Fisher Scientific Stock Performance
NYSE TMO opened at $621.87 on Monday. The company's fifty day moving average is $558.64 and its two-hundred day moving average is $511.84. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $647.00. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The firm has a market capitalization of $229.93 billion, a price-to-earnings ratio of 33.45, a P/E/G ratio of 2.53 and a beta of 0.85.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. During the same quarter in the prior year, the business earned $4.28 earnings per share. The firm's revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.
Thermo Fisher Scientific Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.11%.
Insider Transactions at Thermo Fisher Scientific
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 275 shares of the business's stock in a transaction on Monday, August 24th. The shares were sold at an average price of $627.05, for a total value of $172,438.75. Following the sale, the chief executive officer owned 123,925 shares of the company's stock, valued at $77,707,171.25. The trade was a 0.22% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the transaction, the vice president owned 14,784 shares of the company's stock, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 73,768 shares of company stock valued at $44,122,820. Company insiders own 0.33% of the company's stock.
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Read More
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
